40834. Intravenous Immunoglobulin in Treatment of Severe Clostridium difficile Colitis
Session: Poster Abstract Session: Medical Student Poster Session
Friday, October 4, 2013
Room: Yerba Buena Ballrooms
Background: Clostridium difficile infection is an increasingly common cause of health care-acquired diarrhea  and even with the use of antibiotics and colectomy, there remains a substantial mortality. The aim of our study was to investigate the role of intravenous immunoglobulin (IVIG) on mortality in patients with severe C. difficle colitis.

Methods: Retrospective chart review of patients with C. difficle treated with IVIG in our affiliated hospitals from January 2000 to December 2012 was conducted. Controls were patients who were admitted with the diagnosis of C. difficle and septic shock but did not receive IVIG. Data were compared between these groups.

Results: There were 21 patients in each group and 18 patients in both groups were classified as severe C. difficle infection. Patients in the IVIG group were older [69.8 ± 5.6 vs. 60.9 ± 7 (p=0.05)], had greater leukocytosis  [31,000 ± 7,900 vs. 17,800 ± 5,000 (p=0.01)] and had a higher severity score [5.1 ± 1 vs. 3.6 ± 0.9 (p=0.03)]. Mortality was the primary outcome variable and the two groups had identical mortality rate (22.7%).

Conclusion: Our data demonstrates that although the patients who received IVIG had significantly severe infection, there was no difference in the mortality rate. Prospective controlled studies are needed to assess the true benefit of IVIG in patient with severe C. difficle infection.

Lokesh Shahani, MD, MPH and Janak Koirala, MD, Southern Illinois University School of Medicine, Springfield, IL

Disclosures:

L. Shahani, None

J. Koirala, None

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.